Drugs and patents in ATC class L01EK - Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
AXITINIB	axitinib
INLYTA	axitinib
FOTIVDA	tivozanib hydrochloride
FRUZAQLA	fruquintinib
>Tradename	>Generic Name

Last updated: June 21, 2026

What patents protect VEGFR tyrosine kinase inhibitors in ATC Class L01EK?

ATC L01EK covers small-molecule VEGFR tyrosine kinase inhibitors (TKIs) used in oncology. The patent landscape is dominated by: (1) composition-of-matter for the active ingredient, (2) salt/polymorph and formulation patents for tablets/capsules, (3) method-of-use patents for first-line and subsequent lines, and (4) additional-subject-matter around manufacturing and dosing regimens.

For business planning, the practical question is not “how many patents exist,” but “which patents remain enforceable at the time a generic or next-in-class competitor is likely to be ready.”

Key protected entities by molecule and patent layer

The enforcement profile differs by drug because some molecules have near-monopoly sets of enforceable claims (strong composition-of-matter estates), while others have thinner “blocking” claims but heavier formulation/method-of-use tail risk.

Core patent layers to screen for each VEGFR TKI:

Active ingredient composition-of-matter (compound patent)
Salt forms (if the marketed API is a specific salt)
Polymorph/crystal form (if applicable)
Pharmaceutical composition (tablet/capsule specifics, excipients, particle size)
Process/manufacturing (intermediates, purification, crystallization)
Method-of-use (disease indication and line-of-therapy)
Combination therapy method-of-use (with immuno-oncology agents or other drugs)
Pediatric exclusivity-linked regulatory data exclusivity (affects timing even when patents expire)

How patent estates differ across ATC L01EK

“Older” VEGFR TKIs often have older U.S. filings with earlier composition-of-matter expiration but may have late-expiring formulation or method-of-use patents.
“Later” VEGFR TKIs often show denser branching after initial compound filing: multiple continuation filings, salt/formulation cascades, and regimen patents aligned to pivotal trials.
China and EU-specific filings can extend enforcement geography, but U.S. Orange Book status tends to be the key gating variable for FDA generic entry planning.

When do VEGFR tyrosine kinase inhibitors lose exclusivity in the U.S.?

Exclusivity is a function of (1) patent expiration, (2) regulatory exclusivity (data exclusivity, pediatric exclusivity), and (3) Orange Book listing scope.

What typically drives the “last day to launch”

Patent expiration (with regulatory extensions such as patent term adjustment where applicable)
Pediatric exclusivity (6 months add-on if triggered)
Market exclusivity tied to first FDA approval (rarely the deciding factor once patents are present, but it can matter for “Patent-light” products)
“Unexpired listed patents” in Orange Book that block an ANDA route

Typical U.S. planning approach

Determine the earliest enforceable date among: composition-of-matter, listed method-of-use patents for the approved indications, and any formulation patents.
Identify whether listed method-of-use patents are “skinny” (cover broad indications) or “narrow” (specific regimen endpoints, biomarker subgroups, line-of-therapy).
Map ANDA filing strategy: whether the Paragraph IV challenge can avoid infringement by design-around, carve-out label timing, or non-infringement arguments.

What is the Orange Book status of VEGFR TKI products in ATC L01EK?

Orange Book status determines whether an ANDA applicant must address listed patents via Paragraph IV (or Paragraph III/IB/II positions depending on the status).

How to evaluate Orange Book listings for L01EK

For each marketed VEGFR TKI, screen the Orange Book by:

Listing type: drug substance vs drug product vs method-of-use
Patent expiration dates
“Use code” and covered indications
Whether patents cover monotherapy only or also combination regimens

Operational decision logic for an ANDA:

If method-of-use patents are broad and near expiration, the ANDA is more likely to settle rather than litigate through the 180-day exclusivity window.
If formulation patents are the dominant remaining listings, the ANDA may attempt bioequivalence-driven design around, but formulation patents still frequently trigger litigation.

Which companies are challenging VEGFR TKI patents with Paragraph IV ANDAs?

Paragraph IV challenges are the main engine for generic launch pressure in the U.S. For L01EK, the filing pattern depends on which molecules are:

Patent-expiring soon
Label-scoped to indications with dense method-of-use listings
Subject to recent settlements that define “carve-out” labels and delayed launches

What the competitive filing pattern usually looks like

Early filers challenge the earliest-to-expire listed patents with the highest likelihood of non-infringement or invalidity.
Subsequent filers often copy the “winner” settlement strategy: same carved label, same timing, or same design-around formulation.
Settlement agreements frequently determine who actually gets to launch first, not just who filed first.

What patent litigation affects generic entry for VEGFR TKIs?

VEGFR TKIs are a frequent target of IP litigation because they generate sustained revenue and have dense patent landscapes.

Common litigation outcomes that matter commercially

“Switch” settlements: brand keeps the original label but grants generic a carve-out; brand may also allow limited entry while reserving other indications.
30-month stay triggered by a Paragraph IV suit: launch is delayed even if validity questions later resolve.
Cross-licensing of formulation/process improvements: reduces future litigation but may raise generic launch cost.
Litigation “seriality”: later-expiring formulation patents trigger follow-on suits.

Where damages and injunction risk concentrates

Method-of-use patents: risk concentrates around whether generic label is carved to avoid practicing the patented regimen.
Drug product patents: risk concentrates on whether the ANDA product falls within claim scope for specific formulation parameters.

How does the patent estate for each VEGFR TKI compare by strength and expiry timing?

A useful comparison metric is “time-to-entry” driven by the latest enforceable listed patents for the active indication and by the density of method-of-use listings.

Comparison framework (what to compute per product)

For each VEGFR TKI:

Latest expiration date among all Orange Book-listed patents for the covered indication(s)
Count of listed method-of-use patents
Count of drug product/formulation patents
Presence of combination regimen method-of-use patents with immuno-oncology agents
Recent litigation count tied to those patents (if available from docket sources)

Business implication

High-density method-of-use estates tend to increase settlement frequency and delay generic label expansion.
High-density formulation estates tend to keep litigation focused on product design and could delay generic manufacturing scale-up timelines.

What formulations are protected by VEGFR TKI patents?

Formulation patents often focus on:

Excipients and their ratios
Particle size distribution and milling controls
Coating composition and thickness
Crystalline form controls that affect dissolution and bioavailability
Stability and shelf-life improvements

Table: typical formulation patent scope by product category

Formulation layer	What patents often claim	Why it blocks generics
Immediate-release tablets/capsules	Composition of excipients, manufacturing process parameters	ANDA must show bioequivalence; patent claims can cover formulation details
Salt/crystal form	Specific salt identity and crystal form	Design-around may require different solid form with different behavior
Stability/polymorph control	Storage stability and polymorphic transition prevention	Generic must match performance without using the same process

How many patents cover VEGFR TKI active ingredients and methods of use?

The “number” is less actionable than “how many still expire after the planned launch date.” Still, molecule-by-molecule screening typically reveals:

A compound estate with a primary expiration
Continuations that extend prosecution coverage
Several formulation and method-of-use patents aligned to later trials (including combination regimens)

What patent expiration dates matter most for generic launch of VEGFR TKIs?

For ANDA timing, enforceability hinges on:

The latest expiration date among all patents relevant to the applicant’s proposed label
Whether any patent is subject to pediatric exclusivity extension
Whether the applicant triggers a 30-month stay via Paragraph IV suit

Generic launch scenario mapping

Scenario	Patent posture	Likely timing impact
Clean Paragraph IV win	Fast invalidity/non-infringement outcome	Earlier launch possible if no other listed patents remain
Settlement	Brand grants carve-out and/or delayed launch date	Launch often occurs at settlement-defined date, even if patents later weaken
Multiple follow-on suits	Additional expirations/patents assert after initial resolution	“Whack-a-mole” delays label expansion and sometimes delays full launch

What biosimilar-style risk exists for VEGFR TKIs?

VEGFR TKIs are small molecules, not biologics. “Biosimilar risk” is not the regulatory analogue. The functional equivalents are:

Competitor risk from next-generation small molecules with overlapping indications
Litigation risk from “evergreening” via method-of-use/formulation claims
Regulatory risk from label carve-outs and REMS or safety labeling changes

Which VEGFR TKIs have the highest revenue exposure to patent expiration?

Revenue exposure is determined by:

Share of oncology lines that are still active in treatment standards
Geographic footprint where the molecule is standard-of-care
Competitive intensity from PD-(L)1 combinations where VEGFR TKIs are used in combination regimens

How do VEGFR TKIs compare with other anti-angiogenic agents for patent defensibility?

Compared with:

Anti-VEGF antibodies (different IP and regulatory regimes)
Multi-target TKIs (broader claim scope but different clinical differentiation) VEGFR TKIs often show a denser method-of-use and formulation layering around specific trial combinations, which increases the odds of ongoing litigation even after the core compound patent expires.

What regulatory pathways govern generic entry for VEGFR TKIs in the U.S.?

Generic entry typically uses:

ANDA for small molecules under 505(j)
505(b)(2) for “new formulations” or additional claims where a reference is used

Regulatory timing is tightly coupled to patent and label. If method-of-use patents cover a specific combination regimen, a generic may:

Seek a carve-out label that avoids the patented regimen
Or challenge the method-of-use patent under Paragraph IV and litigate

Key timelines for patent and regulatory gating (how to build a launch calendar)

A workable launch calendar for a VEGFR TKI should include:

Earliest compound expiration (with any PTA/PTA-like adjustments)
Latest Orange Book listed patent expiration for the proposed label
Pediatric exclusivity add-on if triggered
180-day exclusivity risk for first-filer ANDA status
30-month stay trigger date if Paragraph IV suit is filed

Key takeaways

ATC L01EK VEGFR TKIs face a patent-driven market structure where method-of-use and formulation patents often determine the real launch window, not just compound expiration.
Orange Book listings and indication scope are the gating variables for ANDA Paragraph IV strategies.
Generic entry timing is commonly shaped by settlements, 30-month stays, and follow-on formulation/method-of-use enforcement.
“Biosimilar risk” is not the analogue for these small molecules; the relevant analogs are next-in-class competition and litigation-driven design-around and label carve-out dynamics.

FAQs

Which Orange Book use codes most often block ANDA launches for VEGFR TKIs?
Do method-of-use patents for combination regimens (VEGFR TKI + IO therapy) delay generic label expansions more than formulation patents?
How does pediatric exclusivity affect the effective end date for VEGFR TKI exclusivity in the U.S.?
What claim types in VEGFR TKI patents most frequently survive invalidity challenges in Paragraph IV litigation?
When multiple Paragraph IV challengers file against the same VEGFR TKI, how do settlements typically determine first generic launch?

References

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
FDA. 21 U.S.C. § 355(j): Abbreviated New Drug Application (ANDA) framework and Paragraph IV certification provisions. FDA/Statute.

Drugs in ATC Class L01EK

Drugs in ATC Class: L01EK - Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors

Market dynamics and patent landscape for ATC Class L01EK (VEGFR tyrosine kinase inhibitors): exclusivity timing, Orange Book status, Paragraph IV risk, biosimilar-style biologic analogs, and generic entry scenarios